ETF Holdings Breakdown of APLS

APLS institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	54,608	USD 1,221,581
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	9,449	USD 211,374
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	71,614	USD 1,602,005
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	71,614	USD 1,602,005
2025-09-26	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,313	USD 29,372 0.7%
2025-09-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	531	USD 11,878 0.7%
Total =		209,129	USD 4,678,215

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with APLS

Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Grows By 34.0%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 22,090,000 shares, agrowthof34.0% from the July 15th total of 16,490,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio […] - 2025-08-22 05:26:48

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Holdings Lessened by Deutsche Bank AG

Deutsche Bank AG trimmed its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 0.1% in the first quarter, Holdings Channel.com reports. The firm owned 1,776,576 shares of the company’s stock after selling 1,801 shares during the quarter. Deutsche Bank AG’s holdings in Apellis Pharmaceuticals were worth $38,854,000 as of its most recent SEC […] - 2025-08-13 04:52:53

Mackenzie Financial Corp Grows Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Mackenzie Financial Corp increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 14.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,533 shares of the company’s stock after purchasing an additional 5,175 shares during the […] - 2025-08-06 05:57:02

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assetmark Inc.

Assetmark Inc. boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 3,938.7% in the first quarter, HoldingsChannel.com reports. The firm owned 1,252 shares of the company’s stock after acquiring an additional 1,221 shares during the period. Assetmark Inc.’s holdings in Apellis Pharmaceuticals were worth $27,000 as of its most recent filing with […] - 2025-08-06 04:52:49

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective lifted by analysts at JPMorgan Chase & Co. from $35.00 to $37.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 52.89% from the […] - 2025-08-06 03:02:54

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $19.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target raised by Royal Bank Of Canada from $17.00 to $19.00 in a research report sent to investors on Friday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock. A number of other equities research analysts have also recently commented on […] - 2025-08-04 04:26:49

Citigroup Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $46.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target lifted by Citigroup from $41.00 to $46.00 in a report published on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other brokerages have also weighed in on APLS. Morgan Stanley raised their price objective on shares of Apellis Pharmaceuticals […] - 2025-07-30 04:46:46

Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders

(RTTNews) - Apellis Pharmaceuticals Inc. (APLS) announced that the U.S. Food and Drug Administration has approved EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 1 - 2025-07-29 01:03:26

Arizona State Retirement System Lowers Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Arizona State Retirement System cut its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,539 shares of the company’s stock after selling 1,665 shares during the period. Arizona State Retirement System’s holdings in Apellis Pharmaceuticals were worth $427,000 as of its most recent […] - 2025-07-23 06:58:58

Cerity Partners LLC Boosts Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Cerity Partners LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 16.7% during the first quarter, Holdings Channel reports. The firm owned 54,444 shares of the company’s stock after acquiring an additional 7,777 shares during the quarter. Cerity Partners LLC’s holdings in Apellis Pharmaceuticals were worth $1,191,000 at the end of […] - 2025-07-23 06:58:56

Diversified Trust Co Takes $282,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Diversified Trust Co purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 12,878 shares of the company’s stock, valued at approximately $282,000. Other hedge funds and other institutional […] - 2025-07-02 05:18:55

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 147.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 74,325 shares of the company’s stock after buying an additional 44,332 shares during the quarter. Assenagon Asset Management S.A.’s […] - 2025-06-18 04:42:57

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Lifted by Merit Financial Group LLC

Merit Financial Group LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 324.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,762 shares of the company’s stock after buying an additional 25,806 shares during the quarter. Merit […] - 2025-06-09 05:46:43

Wealth Enhancement Advisory Services LLC Purchases 19,641 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Wealth Enhancement Advisory Services LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 140.8% during the 4th quarter, Holdings Channel reports. The firm owned 33,594 shares of the company’s stock after purchasing an additional 19,641 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Apellis Pharmaceuticals were […] - 2025-06-09 04:48:45

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 7.7% on Analyst Upgrade

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shot up 7.7% during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from $26.00 to $29.00. Wells Fargo & Company currently has an equal weight rating on the stock. Apellis Pharmaceuticals traded as high as $18.50 and […] - 2025-06-04 02:01:06

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $29.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target increased by Wells Fargo & Company from $26.00 to $29.00 in a research report released on Monday,Benzinga reports. They currently have an equal weight rating on the stock. APLS has been the subject of a number of other reports. Wedbush cut their price objective on […] - 2025-06-03 02:52:45

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 212,887 shares of the company’s stock after buying an additional 21,822 shares during the quarter. UBS AM a […] - 2025-06-02 05:32:58

14,564 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Purchased by Vident Advisory LLC

Vident Advisory LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 14,564 shares of the company’s stock, valued at approximately $465,000. Several other institutional investors and hedge funds have also recently […] - 2025-05-28 05:31:01

Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Captrust Financial Advisors purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 12,629 shares of the company’s stock, valued at approximately $403,000. Several other hedge funds have also made changes to their positions in APLS. Teacher Retirement System of Texas […] - 2025-05-20 04:47:07

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week Low on Analyst Downgrade

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) reached a new 52-week low on Wednesday after Mizuho lowered their price target on the stock from $30.00 to $20.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $16.61 and last traded at $16.69, with a volume of […] - 2025-05-16 03:00:51

Ameriprise Financial Inc. Boosts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Ameriprise Financial Inc. boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 882,801 shares of the company’s stock after purchasing an additional 22,507 shares during the period. […] - 2025-05-14 07:10:45

Bank of America Corp DE Has $53.62 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Bank of America Corp DE increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 72.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,680,213 shares of the company’s stock after purchasing an additional 705,209 shares during the period. Bank of […] - 2025-05-14 06:12:50

The Manufacturers Life Insurance Company Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

The Manufacturers Life Insurance Company cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 13.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 52,897 shares of the company’s stock after selling 8,324 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Apellis Pharmaceuticals were worth $1,688,000 as of […] - 2025-05-12 06:10:47

Apellis Pharmaceuticals (NASDAQ:APLS) Cut to Outperform at Raymond James

Raymond James cut shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from a strong-buy rating to an outperform rating in a research note released on Friday, MarketBeat reports. They currently have $52.00 price target on the stock, down from their previous price target of $75.00. Other equities research analysts have also issued reports about the […] - 2025-05-12 05:12:48

Robert W. Baird Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective trimmed by Robert W. Baird from $55.00 to $47.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock. A number of other research analysts have also weighed in on APLS. HC Wainwright reiterated a “buy” rating and […] - 2025-05-11 05:40:50

Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Neutral Rating by Bank of America

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock, down from their previous target price of $41.00. Bank […] - 2025-05-11 05:40:50

Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low Following Weak Earnings

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) hit a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $16.65 and last traded at $18.78, with a volume of 490307 shares. The stock had previously closed at $19.12. The company reported ($0.74) […] - 2025-05-08 03:08:52

Legal & General Group Plc Sells 10,879 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Legal & General Group Plc decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 86,771 shares of the company’s stock after selling 10,879 shares during the quarter. Legal & General Group Plc […] - 2025-04-24 05:18:56

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4.9% After Analyst Downgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 4.9% during mid-day trading on Tuesday after Royal Bank of Canada lowered their price target on the stock from $24.00 to $21.00. Royal Bank of Canada currently has a sector perform rating on the stock. Apellis Pharmaceuticals traded as low as $17.52 and last traded […] - 2025-04-24 02:15:10

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $21.00 at Royal Bank of Canada

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Royal Bank of Canada from $24.00 to $21.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector perform rating on the stock. Several other analysts have also commented on APLS. JPMorgan Chase & Co. lifted their price objective […] - 2025-04-22 02:54:45

Back to Listing

Disclaimer